Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00411528 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer
A Phase 2 study of Metastatic Hormone Refractory Prostate Cancer, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 185
- Enrollment target
- 20
- Study locations
NCT00411528: Completed Phase 2 study of Metastatic Hormone Refractory Prostate Cancer, sponsored by Novartis Pharmaceuticals.
NCT00411528 is a Phase 2 study of Metastatic Hormone Refractory Prostate Cancer that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 185 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00411528, a Phase 2 study of Metastatic Hormone Refractory Prostate Cancer, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 185 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer. Additionally, this study will assess the response on measureable disease and the effects on patient-reported outcomes.
Conditions Studied
Interventions
- DRUG prednisone
- DRUG docetaxel
- DRUG Patupilone
Study Locations (20)
Other
- Novartis Investigative Site - Ghent
- Novartis Investigative Site - Bordeaux
- Novartis Investigative Site - Colmar
- Novartis Investigative Site - Lille
- Novartis Investigative Site - Rouen
- Novartis Investigative Site - Strasbourg
Florida
- MD Anderson Cancer Center - Orlando CEPO906A2229 - Orlando
- H. Lee Moffitt Cancer Center/University of South Florida Department of Genitourology - Tampa
- Palm Beach Cancer Institute - West Palm Beach
California
- University of California San Diego Dept of Moores Cancer Center - La Jolla
Colorado
- University of Colorado Dept. of Univ. of Colorado - Aurora
Connecticut
- Norwalk Hospital - Norwalk
District of Columbia
- Georgetown University/Lombardi Cancer Center Dept.of Lombardi Cancer Center - Washington D.C.
Georgia
- NorthWest Georgia Oncology Centers Marietta Center - Marietta
Illinois
- University Chicago Hospital StudyCoordinator:CEPO906A2229 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2006-09 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
What the finished NCT00411528 record still lists
NCT00411528 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% higher).
The record links to 1 condition, with Metastatic Hormone Refractory Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which prednisone is the first listed.
NCT00411528 names 20 study sites across 13 states, led by Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT00411528 about?
NCT00411528 is a clinical study titled "Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer". The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer. Additionally, this study will assess the response on measureable disease and th...
What is the current status of trial NCT00411528?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2006-09. Estimated completion is 2012-09.
What conditions does trial NCT00411528 study?
This clinical trial studies the following conditions: Metastatic Hormone Refractory Prostate Cancer.
What interventions are being tested in trial NCT00411528?
The interventions under investigation include: prednisone (DRUG), docetaxel (DRUG), Patupilone (DRUG).
Who is sponsoring clinical trial NCT00411528?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00411528 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00411528's enrollment target sits among peer trials
185 357th of 2000 higher than 1,641 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia